Innovation

Genetic Test to Diagnose Dilated Cardiomyopathy (DCM)

Brigham and Women's Hospital
posted on 04/04/2012

Technology: The invention is a genetic test using a blood/saliva sample that interrogates the Titin gene for the presence of 72 novel mutations. The inventors have found that approximately 25% of all DCM patients have a truncating mutation in Titin that result in a truncated protein that is the molecular basis of DCM. Also, these mutations are shown to be inherited and have a penetrance of 95%. Patients identified having this mutation can monitor themselves for symptoms of the disease and/or may change their lifestyle for disease prevention. Applications: - Diagnosis of DCM in approximately 25% idiopathic DCM cases - Detection of mutations in 50% of first degree relatives of DCM patients Advantages: - Identify high risk patients for the mutation - Improve treatment options - Simple test - Better than current tests on the market


Innovation Details
 

File Number: 21140 

Other Information: *Investigator(s)*
Daniel Christine E.; Herman Jonathan G.; Seidman Seidman

*Contact*
Amita Joshi, 617-954-9526


IP Protection


License Online

This innovation currently is not available for online licensing. Please contact Mary Auge at Brigham and Women's Hospital for more information.

Request more info via email request more info
People

Case Manager:

Mary Auge Mary Auge

Innovations (0)


Download Technology Brief (PDF)


Followed By

Follow this innovation



No one is following this innovation.

Organization
Communities
Profile
Related Tags

Find more innovations


February 11, 2009

12,881 members 17,317 innovations 176 organizations

Browse

David Kolb, CEO and chairman of the board, Emunamedica LLC.

"We found tremendous value and benefit in using the iBridge Network..."  read more...